These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1227 related items for PubMed ID: 12477155

  • 1. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
    Crook ED, Preddie DC.
    Ethn Dis; 2002; 12(4):S3-49-52. PubMed ID: 12477155
    [Abstract] [Full Text] [Related]

  • 2. [The role of angiotensin II AT1-receptor antagonists in renal and cardiac protection in type-2 diabetes mellitus].
    Ravera M, Deferrari L, Ratto E, Vettoretti S, Parodi D, Deferrari G.
    Ital Heart J Suppl; 2003 Mar; 4(3):210-6. PubMed ID: 12784755
    [Abstract] [Full Text] [Related]

  • 3. [Risk and prevention of diabetic nephropathy].
    Ravera M, Re M, Deferrari G.
    G Ital Nefrol; 2007 Mar; 24 Suppl 38():13-9. PubMed ID: 17922442
    [Abstract] [Full Text] [Related]

  • 4. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB, Britton ML.
    Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
    [Abstract] [Full Text] [Related]

  • 5. Improving microvascular outcomes in patients with diabetes through management of hypertension.
    McGill JB.
    Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
    [Abstract] [Full Text] [Related]

  • 6. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE, Julius S.
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [Abstract] [Full Text] [Related]

  • 7. What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?
    de la Sierra A, Salazar J.
    Adv Ther; 2011 Sep; 28(9):716-27. PubMed ID: 21809181
    [Abstract] [Full Text] [Related]

  • 8. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 9. Therapeutic effects of angiotensin II inhibition or blockade on the progression of chronic renal disease.
    Cantarovich F, Rangoonwala B.
    Int J Clin Pract; 2003 Nov; 57(9):801-22. PubMed ID: 14686572
    [Abstract] [Full Text] [Related]

  • 10. Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.
    Robles NR, Romero B, Fernandez-Carbonero E, Sánchez-Casado E, Cubero JJ.
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):195-200. PubMed ID: 20026868
    [Abstract] [Full Text] [Related]

  • 11. Advances in the treatment of diabetic renal disease: focus on losartan.
    Rayner B.
    Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
    [Abstract] [Full Text] [Related]

  • 12. ACE inhibition or angiotensin receptor blockade: which should we use in diabetic patients?
    Ruilope LM, Segura J, Schiffrin EL.
    J Renin Angiotensin Aldosterone Syst; 2003 Jun; 4(2):74-9. PubMed ID: 12806588
    [Abstract] [Full Text] [Related]

  • 13. The renoprotective effects of RAS inhibition: focus on prevention and treatment of chronic kidney disease.
    Weir MR.
    Postgrad Med; 2009 Jan; 121(1):96-103. PubMed ID: 19179817
    [Abstract] [Full Text] [Related]

  • 14. Diabetic nephropathy.
    Goto A.
    N Engl J Med; 2002 Sep 19; 347(12):947-8; author reply 947-8. PubMed ID: 12239270
    [No Abstract] [Full Text] [Related]

  • 15. Preventing end-stage renal disease in diabetic patients - dual blockade of the renin-angiotensin system (Part II).
    Jacobsen PK.
    J Renin Angiotensin Aldosterone Syst; 2005 Sep 19; 6(2):55-68. PubMed ID: 16470484
    [Abstract] [Full Text] [Related]

  • 16. [Renoprotective effects of ACE inhibitors and AT1 antagonists on diabetic nephropathy beyond blood pressure control].
    Shionoiri H, Yasuda G, Takizawa T, Shionoiri F.
    Nihon Rinsho; 2005 Jun 19; 63 Suppl 6():394-9. PubMed ID: 15999741
    [No Abstract] [Full Text] [Related]

  • 17. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L, Kocks MJ, Laverman GD, Navis G.
    Minerva Med; 2004 Oct 19; 95(5):395-409. PubMed ID: 15467515
    [Abstract] [Full Text] [Related]

  • 18. Optimizing antihypertensive therapy in patients with diabetic nephropathy.
    Ritz E, Rychlík I, Miltenberger-Miltenyi G.
    J Hypertens Suppl; 1998 Sep 19; 16(7):S17-22. PubMed ID: 9855027
    [Abstract] [Full Text] [Related]

  • 19. [Can progression to terminal renal insufficiency be avoided in diabetic nephropathy?].
    Luño J, Valderrábano F.
    An Med Interna; 1998 Nov 19; 15(11):567-71. PubMed ID: 9882851
    [No Abstract] [Full Text] [Related]

  • 20. Anti-diabetic effect of blockade of the renin-angiotensin system.
    Ando K, Fujita T.
    Diabetes Obes Metab; 2006 Jul 19; 8(4):396-403. PubMed ID: 16776746
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 62.